VivoSeq
Nephrology

Renal Insufficiency

104

Pipeline Programs↗

6

Active Trials↗

46

Companies Involved↗

Renal insufficiency is a highly competitive landscape with 104 programs across 46 companies. The most active players are Merck & Co., Bristol-Myers Squibb, Beijing Continent Pharmaceutical Co, Ltd.. 31 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

15/100

Mech. Concentration

7/100

Completion Rate

75/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

11 programs

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1B

Beijing Continent Pharmaceutical Co, Ltd.

1 program

Phase 1R

Rovi Pharmaceuticals Laboratories

1 program

Phase 1A

Ahon Pharmaceutical Co., Ltd.

1 program

Phase 1H

Henan Genuine Biotech Co., Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical7

Rivaroxaban

Wim Janssens

Sodium Thiosulfate

Hope Pharmaceuticals

Cyclophosphamide

Baxter Healthcare Corporation

Losartan

Organon and Co

Gadopentetate Dimeglumine

Bayer

Phase 145

Peginterferon Alfa-2b

Merck & Co.

Iberdomide

Bristol-Myers Squibb

Orforglipron

Eli Lilly

Gefapixant

Merck & Co.

Retatrutide

Eli Lilly

Phase 213

Dexamethasone

Aspen Global Incorporated

Bortezomib

Shilpa Grover, MD, MPH

Linagliptin

Boehringer Ingelheim

LDV/SOF

Gilead

N-Acetylcysteine

Novartis

Phase 38

Everolimus

Novartis

Vildagliptin

Novartis

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Sitagliptin

Zydus Therapeutics Inc.

Calcineurin Inhibitors

Sanofi

Approved31

Mannitol

B. Braun Medical Inc.

Terlipressin

Mallinckrodt

Daridorexant

Idorsia Pharmaceuticals Ltd.

Pirtobrutinib

Eli Lilly

Copanlisib

Bayer

Analysis

Modality Breakdown

93%

Small molecule

111 of 119 classified programs — the dominant modality here.

7%ALL OTHERSPeptide43%Monoclonal antibody33%Protein / enzyme1<1%

Small molecule leads; the ring shows all 119 classified programs, each share of the total. Modality classified for 100% of 120 pipeline programs.

Analysis

Trial Status

79

clinical trials

Completed51 · 65%
Terminated15 · 19%
Recruiting6 · 8%
Unknown status5 · 6%
Withdrawn2 · 3%

Clinical Trials

Trial Activity

79 trials

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
Recruiting·MMedical College of Wisconsin·Phase 2·NCT04240054·41 enrolled
A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency
Recruiting·BBeijing Continent Pharmaceutical Co, Ltd.·Phase 1·NCT07262333·56 enrolled
DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC
Recruiting·FFudan University·Phase 2·NCT06354231·20 enrolled
A Pharmacokinetics and Safety Study of Azvudine Tablets in Subjects With Mild-To-Moderate GFR Decline in Renal Insufficiency and in Healthy Subjects
Recruiting·HHenan Genuine Biotech Co., Ltd.·Phase 1·NCT07001436·40 enrolled
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
Recruiting·Sun Pharmaceutical Industries Limited logoSun Pharmaceutical Industries Limited·Phase 1·NCT07385547·40 enrolled
Study to Investigate Renal Functional Reserve in Healthy Participants and in Participants With Impaired Renal Function.
Recruiting·Bayer logoBayer·Preclinical·NCT07368712·50 enrolled
Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01512667·25 enrolled
A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT07189962·20 enrolled
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency
Completed·SSamsung Medical Center·Phase 2·NCT03667300·209 enrolled
SP2086 Pharmacokinetic Study in Renal Insufficiency Patients
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02815774·30 enrolled
Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency
Completed·Biogen logoBiogen·Phase 3·NCT00709865·420 enrolled
Liraglutide Treatment to Patients With Severe Renal Insufficiency
Completed·—·Phase 4·NCT01394341·40 enrolled
Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT02011490·33 enrolled
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT02045017·81 enrolled
RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography
Completed·SSeoul National University Hospital·Phase 4·NCT00247325
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)